Literature DB >> 19461083

Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.

Thilo Gambichler1, Sarah Grothe, Sebastian Rotterdam, Peter Altmeyer, Alexander Kreuter.   

Abstract

Dysregulation of cell adhesion molecules is associated with progression of malignant melanoma. Immunohistologic study of benign nevi (BN), dysplastic nevi (DN), and primary superficial spreading melanoma (SSM) was performed for carcinoembryonic antigen (CEA) and CEA cell adhesion molecule-1 (CEACAM1) using monoclonal antibodies. We investigated BN (n = 42), DN (n = 22), thin SSM (n = 21), and thick SSM (n = 21). CEA expression in melanomas and DN was significantly increased compared with BN. CEA expression in thick SSM was significantly higher than in DN. Compared with BN, expression of CEACAM1 in melanomas was significantly increased. CEACAM1 expression in thick SSM was significantly increased compared with DN and thin SSM. Our data support the findings of previous studies indicating that cell adhesion molecules of the CEA family may have a role in the development and progression of cutaneous melanoma and potentially serve as prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19461083     DOI: 10.1309/AJCP24KXJVBZXENS

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis.

Authors:  Uwe Rueckschloss; Stefanie Kuerten; Süleyman Ergün
Journal:  Histochem Cell Biol       Date:  2016-09-30       Impact factor: 4.304

2.  Regulation of CEACAM1 transcription in human breast epithelial cells.

Authors:  Marieta Gencheva; Charng-Jui Chen; Tung Nguyen; John E Shively
Journal:  BMC Mol Biol       Date:  2010-11-04       Impact factor: 2.946

3.  Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.

Authors:  Sapoznik Sivan; Faranesh Suzan; Ortenberg Rona; Hamburger Tamar; Barak Vivian; Peretz Tamar; Schachter Jacob; Markel Gal; Lotem Michal
Journal:  Clin Dev Immunol       Date:  2012-01-16

4.  CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells.

Authors:  Zhangguo Chen; Lanfen Chen; Kristi Baker; Torsten Olszak; Sebastian Zeissig; Yu-Hwa Huang; Timothy T Kuo; Ofer Mandelboim; Nicole Beauchemin; Lewis L Lanier; Richard S Blumberg
Journal:  J Exp Med       Date:  2011-12-05       Impact factor: 14.307

5.  Immunohistochemistry: relevance in dermatology.

Authors:  Aparna Palit; Arun C Inamadar
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

Review 6.  Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.

Authors:  Sivan Sapoznik; Ohad Hammer; Rona Ortenberg; Michal J Besser; Tehila Ben-Moshe; Jacob Schachter; Gal Markel
Journal:  Clin Dev Immunol       Date:  2012-04-23

Review 7.  CEACAM1: Expression and Role in Melanocyte Transformation.

Authors:  Gabriela Turcu; Roxana Ioana Nedelcu; Daniela Adriana Ion; Alice Brînzea; Mirela Daniela Cioplea; Lucia Beatrice Jilaveanu; Sabina Andrada Zurac
Journal:  Dis Markers       Date:  2016-08-24       Impact factor: 3.434

8.  Loss of CEACAM1, a Tumor-Associated Factor, Attenuates Post-infarction Cardiac Remodeling by Inhibiting Apoptosis.

Authors:  Yan Wang; Yanmei Chen; Yi Yan; Xinzhong Li; Guojun Chen; Nvqin He; Shuxin Shen; Gangbin Chen; Chuanxi Zhang; Wangjun Liao; Yulin Liao; Jianping Bin
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

9.  Kaposi's Sarcoma-Associated Herpesvirus Interleukin-6 Modulates Endothelial Cell Movement by Upregulating Cellular Genes Involved in Migration.

Authors:  Louise Giffin; John A West; Blossom Damania
Journal:  mBio       Date:  2015-12-08       Impact factor: 7.867

10.  SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.

Authors:  Shira Ashkenazi; Rona Ortenberg; Michal Besser; Jacob Schachter; Gal Markel
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.